Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
|
29754146 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
These results suggested that NEAT1 may promote the development of NSCLC through the miR-377-3p-E2F3 pathway.
|
29085511 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these observations imply that the NEAT1 modulated the expression of E2F3 gene by acting as a ceRNA, which may build up the missing link between the regulatory miRNA network and NSCLC progression.
|
27351135 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Luciferase reporter assay, RT‑qPCR and western blot analysis further demonstrated that E2F3 was a direct target of miR‑433 in NSCLC.
|
29767254 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Our findings suggested that FLVCR1-AS1/miR-573/E2F3 axis was an important signaling pathway in mediating tumorigenesis and progression of NSCLC, and further indicated that FLVCR1-AS1 could be a novel diagnostic biomarker and therapeutic target for NSCLC.
|
30309647 |
2018 |
Focal glomerulosclerosis
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Pathogenesis of focal segmental glomerular sclerosis in a girl with the partial deletion of chromosome 6p.
|
21372519 |
2011 |
Focal Segmental Glomerulosclerosis, Not Otherwise Specified
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Pathogenesis of focal segmental glomerular sclerosis in a girl with the partial deletion of chromosome 6p.
|
21372519 |
2011 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, our data indicate that E2F3 is a key regulator of cell proliferation in a subset of bladder cancer and the 6p22.3 amplicon is a biomarker of aggressive phenotype in this tumor type.
|
24231253 |
2013 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
E2F3 and CDKAL1 are candidate genes from the 6p22 region frequently amplified in bladder cancer.
|
18037967 |
2008 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR-194-5p and E2F transcription factor 3 (E2F3) were determined by means of quantitative reverse transcription and polymerase chain reaction in BC specimens.
|
30570877 |
2019 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development.
|
16909110 |
2007 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplification of E2F3 and NM_017774 was analysed by fluorescence in situ hybridization on a bladder cancer tissue microarray composed of 2317 cancer samples.
|
16953223 |
2006 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for gene copy number and expression analysis by means of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).
|
15122326 |
2004 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
When considered together with the established role of E2F3 in cell cycle progression, these results suggest that the E2F3 gene represents a candidate bladder cancer oncogene that is activated by DNA amplification and overexpression.
|
14716298 |
2004 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated how Rb is integrated to control bladder cancer progression through E2F3 and p53 regulation.
|
27922689 |
2017 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The E2F3 mRNA and protein expression levels were detected in bladder cancer tissues and cell lines, and interestingly, inverse correlations between miR-125b and E2F3 protein level were found in bladder cancer tissues and four E2F3 nonamplified cell lines.
|
20549700 |
2011 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer.
|
16938365 |
2006 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer.
|
16938365 |
2006 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR-194-5p and E2F transcription factor 3 (E2F3) were determined by means of quantitative reverse transcription and polymerase chain reaction in BC specimens.
|
30570877 |
2019 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated how Rb is integrated to control bladder cancer progression through E2F3 and p53 regulation.
|
27922689 |
2017 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The E2F3 mRNA and protein expression levels were detected in bladder cancer tissues and cell lines, and interestingly, inverse correlations between miR-125b and E2F3 protein level were found in bladder cancer tissues and four E2F3 nonamplified cell lines.
|
20549700 |
2011 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
When considered together with the established role of E2F3 in cell cycle progression, these results suggest that the E2F3 gene represents a candidate bladder cancer oncogene that is activated by DNA amplification and overexpression.
|
14716298 |
2004 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
E2F3 and CDKAL1 are candidate genes from the 6p22 region frequently amplified in bladder cancer.
|
18037967 |
2008 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development.
|
16909110 |
2007 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplification of E2F3 and NM_017774 was analysed by fluorescence in situ hybridization on a bladder cancer tissue microarray composed of 2317 cancer samples.
|
16953223 |
2006 |